Effect of prophylactic amiodarone in patients with rheumatic valve disease undergoing valve replacement surgery

Kar, eep Kumar; Dasgupta, Chandan; Goswami, Anupam

doi:10.4103/0971-9784.83986

Cited by 15 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with other antiarrhythmic drugs, amiodarone has higher conversion rate and better sinus rhythm maintenance 19. In this study, the conversion rate of atrial fibrillation and maintenance rate of sinus rhythm of the observation group were 76.2% and 47.6% respectively, which were significantly higher than those of the control group, and the results were similar to the previous research results 20,21. In addition, rate of administration ways of amiodarone can produce different effects.…”

Section: Discussionsupporting

confidence: 86%

Amiodarone in the treatment of atrial fibrillation of patients with rheumatic heart disease after valve replacement

Chen

Lü

et al. 2019

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To explore the efficacy of amiodarone in the treatment of atrial fibrillation for patients with rheumatic heart disease after valve replacement. Methods: Eighty-six patients with rheumatic heart disease who were hospitalized between June 2016 and June 2017 and developed atrial fibrillation after valvular heart valve replacement were randomly divided into a control group and an observation group, 42 cases in each group. The control group was treated with routine medical treatment, while the observation group was given amiodarone on the basis of routine treatment. The cardiac function of the two groups were observed and recorded. Postoperative atrial fibrillation conversion rate, sinus rhythm maintenance rate, intensive care unit (ICU) monitoring time and hospital stay were compared between the two groups. Results: Compared with the control group, the improvement of cardiac function indexes of the observation group was better, and the difference was statistically significant (P<0.05). The atrial fibrillation conversion rate and the maintenance rate of sinus rhythm of the observation group were 76.2% and 47.6% respectively, which were significantly higher than 57.1% and 33.3% of the control group; the differences had statistical significance (P<0.05). The ICU monitoring time and hospitalization time of the patients in the observation group were (1.69±0.91) d and (10.24±1.11) d respectively, which were significantly shorter than (2.83±0.95) d and (14.07±1.17) d in the control group (P<0.05); the differences were statistically significant (P<0.05). Conclusion: Amiodarone can effectively treat valve replacement associated atrial fibrillation of patients with rheumatic heart disease. It can significantly improve the heart function, prevent the recurrence of atrial fibrillation, maintain sinus rhythm after operation, and shorten the time of ICU monitoring and hospitalization. doi: https://doi.org/10.12669/pjms.35.4.1298 How to cite this:Chen K, Qin L, Lu X, Xia T, Gu Q. Amiodarone in the treatment of atrial fibrillation of patients with rheumatic heart disease after valve replacement. Pak J Med Sci. 2019;35(4):---------. doi: https://doi.org/10.12669/pjms.35.4.1298 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionsupporting

confidence: 86%

Amiodarone in the treatment of atrial fibrillation of patients with rheumatic heart disease after valve replacement

Chen

Lü

et al. 2019

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…Previous studies in patients undergoing VR have administered IV amiodarone before CPB and reported reduction in incidence of AF but maintenance of long term SR was not assessed . 17 , 18 …”

Section: Discussionmentioning

confidence: 99%

Flecainide for conversion and maintenance of sinus rhythm after mitral valve replacement in rheumatic atrial fibrillation

Tripathi

Kapoor

Agarwal

et al. 2023

Indian Heart Journal

View full text Add to dashboard Cite

“…In patients undergoing mitral valve replacement, intravenous (IV) amiodarone given before institution of cardiopulmonary bypass significantly reduced the incidence of AF after release of aortic cross clamp as well as at 24 h. 25 , 26 However these studies only used a single dose infusion and did not assess maintenance of SR over long term.…”

Section: Discussionmentioning

confidence: 99%

A pilot study on the acute conversion and maintenance of sinus rhythm in rheumatic atrial fibrillation using oral flecainide

Ghosh

Kapoor

Khanna

et al. 2020

Indian Heart Journal

View full text Add to dashboard Cite

Background Achievement of sinus rhythm (SR) is an important goal in rheumatic atrial fibrillation (AF). Studies in rheumatic AF have often used amiodarone for rhythm control. Flecainide has not been studied in these patients due to concerns of underlying structural heart disease. Methods Pharmacological cardioversion by oral single loading dose (SLD) of Flecainide (4 mg/kg, ≤300 mg) was tested in 50 patients with rheumatic AF (MVA 1.51 ± 0.19 mm 2 , age 46.2 ± 10.28 yrs, AF duration 3.10 ± 1.7 yrs, LA size: 44.42 ± 7.48 mm). Non-converters underwent DC cardioversion (DCC) at 24 h. All patients received oral flecainide and ββ/diltiazem at discharge. Results At 24 h, 38/50 (76%) achieved SR (2 with SLD; 36 after DCC). At 30 days (mean Flecainide dose 116.5 ± 10.5 mg) successful maintenance of SR was noted in 31/38 (89%). At 1 year, 30/38 (79%) of the initial converters and 60% of the overall population maintained SR. Those in SR had significantly better NYHA Class (1.1 ± 0.12 vs 1.3 ± 0.10, p = 0.03) and mean PCS8 score (50.11 ± 5.337 vs 46.84 ± 5.379, p = 0.02). AF duration (OR 0.594 CI 0.375–0.940, p = 0.02) and LA size (OR 0.840, CI 0.757–0.933, p = 0.001) were found to be the only significant predictors of successful outcomes. Patients with AF duration <3.5 years and LA size <51 mm had 85% and 75% chance of maintaining SR at 1 year, respectively. Conclusion Flecainide is safe and effective for achieving and maintaining SR in patients of rheumatic AF who are unlikely to have underlying coronary artery disease or ventricular dysfunction.

show abstract

Effect of prophylactic amiodarone in patients with rheumatic valve disease undergoing valve replacement surgery

Cited by 15 publications

References 25 publications

Amiodarone in the treatment of atrial fibrillation of patients with rheumatic heart disease after valve replacement

Amiodarone in the treatment of atrial fibrillation of patients with rheumatic heart disease after valve replacement

Flecainide for conversion and maintenance of sinus rhythm after mitral valve replacement in rheumatic atrial fibrillation

A pilot study on the acute conversion and maintenance of sinus rhythm in rheumatic atrial fibrillation using oral flecainide

Contact Info

Product

Resources

About